Overcoming antimicrobial resistance by targeting resistance mechanisms

被引:90
作者
Poole, K [1 ]
机构
[1] Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada
关键词
D O I
10.1211/0022357011775514
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Three mechanisms of antimicrobial resistance predominate in bacteria:antibiotic inactivation, target site modification, and altered uptake by way of restricted entry and/or enhanced efflux. Many of these involve enzymes OF. transport proteins whose activity can be targeted directly in an attempt to compromise resistance and, thus, potentiate antimicrobial activity. Alternatively, novel agents unaffected by these resistance mechanisms can be developed. Given the ongoing challenge posed by antimicrobial resistance in bacteria, targeting resistance in this way may be our best hope at prolonging the antibiotic era.
引用
收藏
页码:283 / 294
页数:12
相关论文
共 165 条
[11]   Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection [J].
Bergeron, J ;
Ammirati, M ;
Danley, D ;
James, L ;
Norcia, M ;
Retsema, J ;
Strick, CA ;
Su, WG ;
Sutcliffe, J ;
Wondrack, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2226-2228
[12]   The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :458-460
[13]   Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].
Brenwald, NP ;
Gill, MJ ;
Wise, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035
[14]   Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins [J].
Brisse, S ;
Milatovic, D ;
Fluit, AC ;
Verhoef, J ;
Martin, N ;
Scheuring, S ;
Köhrer, K ;
Schmitz, FJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :2051-2055
[15]   Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones [J].
Brisse, S ;
Fluit, AC ;
Wagner, U ;
Heisig, P ;
Milatovic, D ;
Verhoef, J ;
Scheuring, S ;
Köhrer, K ;
Schmitz, FJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2513-2516
[16]  
Bush K, 1998, ADV EXP MED BIOL, V456, P71
[17]  
Bush K, 1999, CURR PHARM DESIGN, V5, P839
[18]  
Buynak JD, 2000, BIOORG MED CHEM LETT, V10, P853, DOI 10.1016/S0960-894X(00)00098-6
[19]   The synthesis and evaluation of 2-substituted-7(alkylidene)cephalosporin sulfones as β-lactamase inhibitors [J].
Buynak, JD ;
Doppalapudi, VR ;
Rao, AS ;
Nidamarthy, SD ;
Adam, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (09) :847-851
[20]   FACTORS INFLUENCING THE ACCUMULATION OF CIPROFLOXACIN IN PSEUDOMONAS-AERUGINOSA [J].
CELESK, RA ;
ROBILLARD, NJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (11) :1921-1926